|Bid||13.23 x 4000|
|Ask||13.24 x 3100|
|Day's range||13.20 - 13.39|
|52-week range||13.20 - 19.97|
|Beta (5Y monthly)||1.08|
|PE ratio (TTM)||10.06|
|Forward dividend & yield||0.84 (6.21%)|
|Ex-dividend date||30 Mar 2021|
|1y target est||19.14|
Icahn Enterprises and Takeda Pharmaceutical are two intriguing hedges against sky-high inflation rates.
CAMBRIDGE, Mass., November 30, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it is enhancing its Corporate Social Responsibility (CSR) Program in the U.S., making an initial commitment of $20 million its first year supporting organizations in the U.S. to help improve equity among underrepresented communities in the areas of health, education, the environment and access to nutrition/food. Takeda also announced its current 2021 U.S. CSR Program gra
The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.